Evaluating Central Line Hub Contamination Using a Novel Capping Device
Primary Purpose
Catheter-related Bloodstream Infection Due to Central Venous Catheter
Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Disinfecting Cap
Sponsored by
About this trial
This is an interventional prevention trial for Catheter-related Bloodstream Infection Due to Central Venous Catheter
Eligibility Criteria
Inclusion Criteria:
- Adult patients with peripherally inserted central catheters (PICC) inserted during their index hospitalization plus 5 or more consecutive PICC line days were consented and enrolled.
Exclusion Criteria:
- Minors and adult inpatients without PICCs or with PICCs for < 5 days
Sites / Locations
- NorthShore: Evanston HospitalRecruiting
- NorthShore: Glenbrook HospitalRecruiting
- NorthShore: Highland Park HospitalRecruiting
- NorthShore: Skokie HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Glenbrook Hospital
Evanston, Highland Park, Skokie Hospitals
Arm Description
Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months. Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)
Outcomes
Primary Outcome Measures
Quantitative contamination of intraluminal fluid from central venous catheters (discard) as measured in CFU/ml
For the research project, we will monitor the colonization of access port colonization in routine as well as SwabCap™ cared for lines as follows:
Specimen sampling will be done by obtaining one specimen of 1.0 mL of aspirate will be withdrawn from each unused catheter lumen during first morning rounds in a separate syringe; then placed in a epdiatric Isolator tube.
Secondary Outcome Measures
Central line associated bloodstream infections
Central line-associated bloodstream infections (CLABSI) as defined by the National Healthcare Safety Network (NHSN) of all patients throughout 4 hospitals in 2009-2011.
Full Information
NCT ID
NCT01301300
First Posted
February 22, 2011
Last Updated
February 22, 2011
Sponsor
NorthShore University HealthSystem
1. Study Identification
Unique Protocol Identification Number
NCT01301300
Brief Title
Evaluating Central Line Hub Contamination Using a Novel Capping Device
Official Title
Demonstration of Central Line Hub Contamination Reduction Using a Novel Capping Device
Study Type
Interventional
2. Study Status
Record Verification Date
February 2011
Overall Recruitment Status
Unknown status
Study Start Date
April 2010 (undefined)
Primary Completion Date
September 2011 (Anticipated)
Study Completion Date
December 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
NorthShore University HealthSystem
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Excelsior Medical has developed SwabCap™, a luer access valve disinfection cap. The SwabCap™ provides passive disinfection of valve top and threads without activating the luer access valve. This product promotes technique standardization and compliance in cleansing of the luer access valve prior to access. It acts as a physical barrier from touch and airborne contamination for up to 96 hours. This product has been endorsed and will be adopted for use at NorthShore University HealthSystem as a quality improvement initiative. This research study protocol is designed to confirm the anticipated benefit of this change in practice at NorthShore during the planned implementation and use.
If the product performs as it has been designed to, the baseline rate of hub and subsequently intraluminal contamination will be diminished, thereby protecting patients with central lines from bloodstream infections due to contaminated hubs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Catheter-related Bloodstream Infection Due to Central Venous Catheter
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
600 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Glenbrook Hospital
Arm Type
Active Comparator
Arm Description
Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
Arm Title
Evanston, Highland Park, Skokie Hospitals
Arm Type
Active Comparator
Arm Description
Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.
Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)
Intervention Type
Device
Intervention Name(s)
Disinfecting Cap
Other Intervention Name(s)
SwabCap SC003 2000
Intervention Description
Replace standard practice with using the disinfecting cap
Primary Outcome Measure Information:
Title
Quantitative contamination of intraluminal fluid from central venous catheters (discard) as measured in CFU/ml
Description
For the research project, we will monitor the colonization of access port colonization in routine as well as SwabCap™ cared for lines as follows:
Specimen sampling will be done by obtaining one specimen of 1.0 mL of aspirate will be withdrawn from each unused catheter lumen during first morning rounds in a separate syringe; then placed in a epdiatric Isolator tube.
Time Frame
Throughout the study with enrolled subjects (The catheter must have been in place for a period of 5 or more days before the first sample is taken.)
Secondary Outcome Measure Information:
Title
Central line associated bloodstream infections
Description
Central line-associated bloodstream infections (CLABSI) as defined by the National Healthcare Safety Network (NHSN) of all patients throughout 4 hospitals in 2009-2011.
Time Frame
Throughout the study and from historical data
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients with peripherally inserted central catheters (PICC) inserted during their index hospitalization plus 5 or more consecutive PICC line days were consented and enrolled.
Exclusion Criteria:
Minors and adult inpatients without PICCs or with PICCs for < 5 days
Facility Information:
Facility Name
NorthShore: Evanston Hospital
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sue Boehm, RN
Phone
847-926-5860
Email
sboehm@northshore.org
First Name & Middle Initial & Last Name & Degree
Marc Wright, MS
Phone
8475702420
Email
mwright@northshore.org
Facility Name
NorthShore: Glenbrook Hospital
City
Glenview
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sue Boehm, RN
Phone
847-926-5860
Email
sboehm@northshore.org
First Name & Middle Initial & Last Name & Degree
Marc Wright, MS
Phone
8475702420
Email
mwright@northshore.org
Facility Name
NorthShore: Highland Park Hospital
City
Highland Park
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sue Boehm, RN
Phone
847-926-5860
Email
sboehm@northshore.org
First Name & Middle Initial & Last Name & Degree
Marc Wright, MS
Phone
8475702420
Email
mwright@northshore.org
Facility Name
NorthShore: Skokie Hospital
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sue ' Boehm, RN
Phone
847-926-5860
Email
sboehm@northshore.org
First Name & Middle Initial & Last Name & Degree
Marc Wright, MS
Phone
8475702420
12. IPD Sharing Statement
Learn more about this trial
Evaluating Central Line Hub Contamination Using a Novel Capping Device
We'll reach out to this number within 24 hrs